文摘
摘要目的:探索认知,脑电图和MRI特征COVID-19幸存者10个月后出院。
背景:越来越意识到持久的神经系统后遗症的COVID-19担忧他们的发病机理和可逆性。纵向研究与长期随访和结构化的神经心理学和脑电图评估仍然缺乏。
设计/方法:成人患者最近的诊断COVID-19接受神经心理学评估和2个月内19-channel-EEG(基线,N = 49)和10个月(随访,N = 33)后出院。脑部核磁共振得到36个患者在基线。匹配的健康对照组都包括在内。使用eLORETA,脑电图区域电流密度估计和线性滞后连接值。总大脑白质hyperintensities(负责人)卷测量。患者临床和工具之间的数据进行评估和控制基线,并在患者群和子组/没有味觉障碍/嗅觉减退。在每个计算是计算结果之间的相关性。
结果:在基线、53%和28%的患者显示认知和精神病理学的干扰,分别与关联的执行功能障碍急性期呼吸窘迫。与健康对照组相比,病人还显示更高的三角洲区域电流密度和连接带,与执行相关的表演,和更大的研究负责人负载,与口头记忆关联赤字。减少认知障碍和δ乐队脑电图连接观察随着时间的推移,而精神病态的症状持续不减。急性味觉障碍/嗅觉减退患者显示低于那些没有改善在记忆测试。低脑电图三角洲乐队在基线认知功能在后续的预测更糟。
结论:COVID-19病人显示相关的认知,脑电图和MRI改变2个月后出院。认知和脑电图的发现提高10个月。味觉障碍和急性COVID-19期间嗅觉减退与脆弱性增加记忆功能。
披露:佐丹奴Cecchetti没有披露。Federica Agosta已收到个人薪酬在500 - 4999美元的范围在飞利浦的演讲人。Federica Agosta已收到个人薪酬在500 - 4999美元的范围作为一个编辑,副主编或编辑顾问委员会成员,爱思唯尔公司制度的Elisa Canu已经收到了来自意大利卫生部的研究支持。西尔维亚Basaia没有披露。亚历山德拉巴比里没有披露。Cardamone太太没有披露。玛丽亚Paola; 8:32没有披露。Veronica Castelnovo没有披露。卡米拉Cividini没有披露。马可Cursi没有披露。 Marco Vabanesi has nothing to disclose. Dr. Impellizzeri has nothing to disclose. Dr. Lazzarin has nothing to disclose. Dr. Fanelli has nothing to disclose. GIACOMO GIACALONE has nothing to disclose. Andrea Falini has nothing to disclose. Monica Falautano has nothing to disclose. Patrizia Rovere-Querini has nothing to disclose. Luisa Roveri has nothing to disclose. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
